Cargando…

Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX

Endoscopic biliary drainage is the recommended 1(st)-line treatment for malignant biliary obstruction. Although a high incidence of febrile neutropenia has been reported in patients treated with FOLFIRINOX and a biliary stent, it remains unknown whether the biliary stent contributes to patient survi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshikawa-Kimura, Akie, Taira, Koichi, Maruyama, Hirotsugu, Ishikawa-Kakiya, Yuki, Yamamura, Masafumi, Tanoue, Kojiro, Hagihara, Atsushi, Uchida-Kobayashi, Sawako, Enomoto, Masaru, Kimura, Kenjiro, Tanaka, Shogo, Amano, Ryosuke, Takemura, Shigekazu, Ohfuji, Satoko, Tanaka, Fumio, Nagami, Yasuaki, Fujiwara, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750610/
https://www.ncbi.nlm.nih.gov/pubmed/36626539
http://dx.doi.org/10.1097/MD.0000000000032150
_version_ 1784850293532393472
author Yoshikawa-Kimura, Akie
Taira, Koichi
Maruyama, Hirotsugu
Ishikawa-Kakiya, Yuki
Yamamura, Masafumi
Tanoue, Kojiro
Hagihara, Atsushi
Uchida-Kobayashi, Sawako
Enomoto, Masaru
Kimura, Kenjiro
Tanaka, Shogo
Amano, Ryosuke
Takemura, Shigekazu
Ohfuji, Satoko
Tanaka, Fumio
Nagami, Yasuaki
Fujiwara, Yasuhiro
author_facet Yoshikawa-Kimura, Akie
Taira, Koichi
Maruyama, Hirotsugu
Ishikawa-Kakiya, Yuki
Yamamura, Masafumi
Tanoue, Kojiro
Hagihara, Atsushi
Uchida-Kobayashi, Sawako
Enomoto, Masaru
Kimura, Kenjiro
Tanaka, Shogo
Amano, Ryosuke
Takemura, Shigekazu
Ohfuji, Satoko
Tanaka, Fumio
Nagami, Yasuaki
Fujiwara, Yasuhiro
author_sort Yoshikawa-Kimura, Akie
collection PubMed
description Endoscopic biliary drainage is the recommended 1(st)-line treatment for malignant biliary obstruction. Although a high incidence of febrile neutropenia has been reported in patients treated with FOLFIRINOX and a biliary stent, it remains unknown whether the biliary stent contributes to patient survival. Thus, we aimed to elucidate the effects of biliary stents on the survival of patients with advanced pancreatic cancer treated with modified FOLFIRINOX (mFFX). We retrospectively reviewed medical charts of patients with advanced pancreatic cancer treated with mFFX between January 2014 and April 2020. We compared the overall survival (OS) of patients with and without biliary stent during mFFX treatment and examined the independent effect on mortality using propensity score matching. Overall, we included 89 patients (stent group, n = 24; non-stent group, n = 65). The proportion of patients with pancreatic head cancer was significantly higher in the stent group than in the non-stent group (P < .01). Stratification analysis in patients with pancreatic head cancer revealed that OS was significantly shorter in the stent group than in the non-stent group (P = .03). After propensity score matching, 19 pairs of patients in each group were analyzed. The stent group revealed a significantly shorter survival than the non-stent group (median OS, 10.3 vs 24.9 months; P < .01). The incidences of febrile neutropenia (P = .01) and biliary tract-related events that required biliary stenting or stent replacement (P < .01) were significantly higher in the stent group than in the non-stent group. Stent insertion was an independent risk factor for overall mortality. Biliary stents may reduce survival in patients with advanced pancreatic cancer. The rate of febrile neutropenia was higher in the stent group than in the non-stent group. There is a need to assess the patient’s condition with discretion and develop a treatment strategy with short prognosis in mind after stent insertion.
format Online
Article
Text
id pubmed-9750610
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-97506102022-12-28 Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX Yoshikawa-Kimura, Akie Taira, Koichi Maruyama, Hirotsugu Ishikawa-Kakiya, Yuki Yamamura, Masafumi Tanoue, Kojiro Hagihara, Atsushi Uchida-Kobayashi, Sawako Enomoto, Masaru Kimura, Kenjiro Tanaka, Shogo Amano, Ryosuke Takemura, Shigekazu Ohfuji, Satoko Tanaka, Fumio Nagami, Yasuaki Fujiwara, Yasuhiro Medicine (Baltimore) 4500 Endoscopic biliary drainage is the recommended 1(st)-line treatment for malignant biliary obstruction. Although a high incidence of febrile neutropenia has been reported in patients treated with FOLFIRINOX and a biliary stent, it remains unknown whether the biliary stent contributes to patient survival. Thus, we aimed to elucidate the effects of biliary stents on the survival of patients with advanced pancreatic cancer treated with modified FOLFIRINOX (mFFX). We retrospectively reviewed medical charts of patients with advanced pancreatic cancer treated with mFFX between January 2014 and April 2020. We compared the overall survival (OS) of patients with and without biliary stent during mFFX treatment and examined the independent effect on mortality using propensity score matching. Overall, we included 89 patients (stent group, n = 24; non-stent group, n = 65). The proportion of patients with pancreatic head cancer was significantly higher in the stent group than in the non-stent group (P < .01). Stratification analysis in patients with pancreatic head cancer revealed that OS was significantly shorter in the stent group than in the non-stent group (P = .03). After propensity score matching, 19 pairs of patients in each group were analyzed. The stent group revealed a significantly shorter survival than the non-stent group (median OS, 10.3 vs 24.9 months; P < .01). The incidences of febrile neutropenia (P = .01) and biliary tract-related events that required biliary stenting or stent replacement (P < .01) were significantly higher in the stent group than in the non-stent group. Stent insertion was an independent risk factor for overall mortality. Biliary stents may reduce survival in patients with advanced pancreatic cancer. The rate of febrile neutropenia was higher in the stent group than in the non-stent group. There is a need to assess the patient’s condition with discretion and develop a treatment strategy with short prognosis in mind after stent insertion. Lippincott Williams & Wilkins 2022-12-09 /pmc/articles/PMC9750610/ /pubmed/36626539 http://dx.doi.org/10.1097/MD.0000000000032150 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 4500
Yoshikawa-Kimura, Akie
Taira, Koichi
Maruyama, Hirotsugu
Ishikawa-Kakiya, Yuki
Yamamura, Masafumi
Tanoue, Kojiro
Hagihara, Atsushi
Uchida-Kobayashi, Sawako
Enomoto, Masaru
Kimura, Kenjiro
Tanaka, Shogo
Amano, Ryosuke
Takemura, Shigekazu
Ohfuji, Satoko
Tanaka, Fumio
Nagami, Yasuaki
Fujiwara, Yasuhiro
Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX
title Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX
title_full Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX
title_fullStr Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX
title_full_unstemmed Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX
title_short Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX
title_sort influence of a biliary stent in patients with advanced pancreatic cancer treated with modified folfirinox
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750610/
https://www.ncbi.nlm.nih.gov/pubmed/36626539
http://dx.doi.org/10.1097/MD.0000000000032150
work_keys_str_mv AT yoshikawakimuraakie influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox
AT tairakoichi influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox
AT maruyamahirotsugu influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox
AT ishikawakakiyayuki influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox
AT yamamuramasafumi influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox
AT tanouekojiro influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox
AT hagiharaatsushi influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox
AT uchidakobayashisawako influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox
AT enomotomasaru influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox
AT kimurakenjiro influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox
AT tanakashogo influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox
AT amanoryosuke influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox
AT takemurashigekazu influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox
AT ohfujisatoko influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox
AT tanakafumio influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox
AT nagamiyasuaki influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox
AT fujiwarayasuhiro influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox